| Oct. 22, 2009 |
|
The Supreme Court of Canada Will Not Review the Saskatchewan Court of Appeal Judgment Overturning a Class Certification Order in VIOXX® Action
|
| Oct. 19, 2009 |
|
Merck Statement on U.S. Speaker Fees Company Achieves another Milestone in Its Ongoing Transparency Initiative |
| Sep. 25, 2009 |
|
Merck Statement About JANUVIA™ (sitagliptin) and JANUMET™ (sitagliptin/metformin) |
| Sep. 24, 2009 |
|
Merck Statement on HIV Vaccine Trial |
| Aug. 11, 2009 |
|
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court |
| Jul. 29, 2009 |
|
Statement by Merck & Co., Inc., Regarding FOSAMAX® (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw |
| Jun. 20, 2009 |
|
Merck & Co., Inc. Statement on Medicare Part D Assistance |
| Jun. 12, 2009 |
|
Merck Statement in Response to the FDA's June 12, 2009 Communication with Updated Information on Leukotriene Inhibitors, Including SINGULAIR® (montelukast sodium) |
| |
|
|
Patient Product Information |
| May 29, 2009 |
|
Merck Statement on United States Patent & Trademark Office Decision to Reexamine the SINGULAIR® Patent |
| May 11, 2009 |
|
Merck & Co., Inc. Statement on Health Reform Meeting with President Obama |
| May 08, 2009 |
|
Merck Statement on California Court Ruling Denying Certification of Class of Plaintiffs Seeking Reimbursement for VIOXX® Costs |
| Mar. 17, 2009 |
|
Merck Statement on New Jersey Court Ruling Denying Certification of Class of Plaintiffs Seeking Reimbursement for Out-of-Pocket VIOXX® Costs |
| Jul. 08, 2008 |
|
UPDATED: Merck Comments on Questions about Adverse Events Reported Following Vaccination with GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] |
| |
|
|
Patient Product Information |
